Symetis Gets CHF23mm Through Its Series B Round

Deal summary reprinted from Strategic Transactions - July 2009

Symetis SA, which is developing the Acurate self-positioning device for percutaneous aortic valve replacement, has raised CHF23mm ($21.3mm) through its Series B venture round. Vinci Capital & Renaissance and Wellington Partners led the financing and were joined by fellow first-time investor Banexi Venture Partners and current shareholders Aravis Venture, BioMedInvest, Novartis Venture Funds, Truffle Capital, and individual backers. Symetis will use some of the funds to start in vivo preclinical testing of its Acurate TF transfemoral device.

Find out more about what our Strategic Transactions - The Device Deal Database can do for you.

Strategic Transactions - The Device Deal Database provides expanded information, including:

- Comprehensive Deal Records
- Complete Financial Information
- Extensive Company Profiles
- Access to important SEC Documents
- Links to related articles

Contact: James DeFalco at: +1 (203) 838-4401 x104 or [email protected].